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the pathogenesis of this neonatal cholangiopathy
Extra hepatic biliary atresia is a relatively common cholestatic
liver disease affecting one in 10–20,000 newborns which develop
an obstructive cholangiopathy. The etio-pathogenesis of this
entity is not fully understood. A number of mechanisms have
been proposed to explain the rapid development of the character-
istic destructive cholangiopathy which requires immediate surgi-
cal intervention, preferably within 4–8 weeks after birth. These
include among others, an infectious etiology, i.e., by group C Rota
virus, cytomegalic virus infection, immune mediated injury as a
result of immune dysregulation, a graft versus host induced cho-
langiocyte injury by maternal chimeric lymphocytes, and a
genetic etiology which leads to an undeﬁned susceptibility to
environmental infectious agents or toxins.
In this issue of the journal, Miethke and co-workers have used
an experimental mouse model of rhesus Rota virus (RRV) infec-
tion in which intraperitoneal injection of RRV within 3 days of
birth leads to a natural killer cell (NK) mediated inﬂammatory
cholangiopathy in neonatal balb/c mice by day 7. Previously,
these investigators have elucidated the role of interferon c,
CD8+, and NK cells in the initiation of neonatal cholangiopathy
in this model. In a set of elegant and exhaustive in vivo and
in vitro experiments, the authors now provide evidence for the
role of T regulatory cells (Tregs) in the development of biliary
atresia in the mouse model. Data obtained suggest that early,
postnatal absence of T regulatory cells (Tregs) is a key factor in
development of a cholangiopathy, allowing hepatic dendritic cells
(DC) to activate NK cells, leading to the initiation of bile duct
injury characteristic for biliary atresia. It is not yet known
whether a similar mechanism of immaturity of the immune sys-
tem (and decreased or absence of Treg activity) is also present in
the early neonatal period in human neonates with biliary atresia.
Conﬁrmation of these results in babies with biliary atresia is dif-
ﬁcult and probably impossible. However, indirect support for a
similar mechanism in humans is provided in this paper by the
increased expression of Tregs signature genes in liver tissue
obtained from nine babies with biliary atresia. In summary, this
report adds further important information on the mechanism of
immune mediated biliary injury in experimental biliary atresia.Journal of Hepatology 20
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E-mail address: shouval@cc.huji.ac.ilImpact of anti-viral therapy on incidence of hepatocellular
carcinoma and survival of hepatitis C patients with advanced
ﬁbrosis
A 2008 US NIH consensus statement regarding the impact of anti-
viral treatment against hepatitis B on the incidence of complica-
tions and outcome of chronic HBV included the following state-
ment: ‘‘The major goals of anti-HBV therapy are to prevent the
development of progressive disease, speciﬁcally cirrhosis and liver
failure, as well as hepatocellular carcinoma development and subse-
quent death. To date, no RCTs of anti-HBV therapies have demon-
strated a beneﬁcial impact on overall mortality, liver-speciﬁc
mortality, or development of hepatocellular carcinoma” (http://con-
sensus.nih.gov/2008/statementhep).
A similar question mark has been raised regarding the impact
of anti-viral therapy in hepatitis C virus (HCV) infection on the
incidence of hepatocellular carcinoma (HCC) and other long-term
complications of chronic hepatitis C.
In the absence of prospective controlled trials, it is still difﬁ-
cult to assess the long-term beneﬁcial effect of anti-viral therapy
and sustained anti-viral response (SVR) on the natural course and
complications of chronic HCV infection in general and HCC in par-
ticular. Previous reports have demonstrated only a marginal ben-
eﬁcial impact of interferon therapy on the incidence of HCC as
concluded by a meta-analysis by Craxi and Camma (Clin Liver
Dis 2005;9:329). In this issue of the journal, Cardoso and co-work-
ers report their single center retrospective analysis on the impact
of anti-viral therapy (primarily by combined peginterferon and
ribavirin) on the incidence of HCV associated HCC in a cohort of
127 patients with bridging ﬁbrosis (F3) and 180 patients with cir-
rhosis (F4). The main ﬁnding of this report is a signiﬁcantly lower
incidence rate of HCC in patients who achieved an SVR as com-
pared to non-SVR patients. Multi-variate analysis conﬁrmed that
non-SVR was an independent predictor of HCC, of liver related
complications (ascites, bleeding esophageal varices) and liver
related mortality. Surprisingly, the overall SVR rate of 33% is
lower than expected in a population of patients which includes
also genotype 2 and 3 subjects with chronic HCV. This result
may however explain the relatively higher rate of HCC in the
present study population as compared to another study per-
formed in Italy (Bruno S et al. Hepatology 2007:45:579). Although
these results which report a relatively short mean follow-up of
3.5 years may seem obvious to the practicing hepatologist, the
data provided add important information. The conclusions
derived from this study deliver a message emphasizing the
importance of anti-viral therapy in patients with advanced ﬁbro-
sis and compensated cirrhosis despite the clinical experience that
such patients may not tolerate this treatment very well.10 vol. 52 j 621
